Notice for olaparib (AstraZeneca Pty Ltd)
Active ingredients
olaparib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the maintenance treatment of patients with newly diagnosed BRCA-mutated advanced ovarian cancer.
Therapeutic area
Oncology